Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
Harmony Biosciences (Nasdaq: HRMY) has appointed Ron Philip to its Board of Directors. Philip, currently President and CEO of Orbital Therapeutics, brings 30 years of experience in company building, organizational growth, and therapeutic development. His notable previous role was CEO of Spark Therapeutics, where he led the commercial launch of a novel gene therapy for inherited blindness and expanded the company's therapeutic platform.
Philip's extensive background includes leadership positions at Pfizer and Wyeth, serving as regional president for Africa/Middle East and heading various strategic initiatives. He currently serves on the boards of City Therapeutics and Life Sciences Cares Pennsylvania. The appointment aligns with Harmony's focus on pipeline expansion through business development, as the company aims to leverage Philip's expertise in identifying new technologies that benefit patients while creating shareholder value.
Harmony Biosciences (Nasdaq: HRMY) ha nominato Ron Philip nel suo Consiglio di Amministrazione. Philip, attualmente Presidente e CEO di Orbital Therapeutics, porta con sé 30 anni di esperienza nella costruzione di aziende, nella crescita organizzativa e nello sviluppo terapeutico. Il suo ruolo precedente più significativo è stato CEO di Spark Therapeutics, dove ha guidato il lancio commerciale di una nuova terapia genica per la cecità ereditaria e ha ampliato la piattaforma terapeutica dell'azienda.
Il vasto background di Philip include posizioni di leadership presso Pfizer e Wyeth, dove ha ricoperto il ruolo di presidente regionale per Africa/Medio Oriente e ha guidato varie iniziative strategiche. Attualmente, fa parte dei consigli di amministrazione di City Therapeutics e Life Sciences Cares Pennsylvania. La nomina si allinea con l'obiettivo di Harmony di espandere il proprio portafoglio attraverso lo sviluppo commerciale, poiché l'azienda mira a sfruttare l'esperienza di Philip nell'identificare nuove tecnologie che possano beneficiare i pazienti, creando al contempo valore per gli azionisti.
Harmony Biosciences (Nasdaq: HRMY) ha nombrado a Ron Philip en su Junta Directiva. Philip, actualmente Presidente y CEO de Orbital Therapeutics, aporta 30 años de experiencia en la construcción de empresas, el crecimiento organizacional y el desarrollo terapéutico. Su notable rol anterior fue como CEO de Spark Therapeutics, donde lideró el lanzamiento comercial de una novedosa terapia génica para la ceguera hereditaria y amplió la plataforma terapéutica de la empresa.
El extenso historial de Philip incluye posiciones de liderazgo en Pfizer y Wyeth, sirviendo como presidente regional para África/Medio Oriente y encabezando varias iniciativas estratégicas. Actualmente, forma parte de las juntas de City Therapeutics y Life Sciences Cares Pennsylvania. La designación se alinea con el enfoque de Harmony en la expansión de su cartera a través del desarrollo empresarial, ya que la compañía busca aprovechar la experiencia de Philip en la identificación de nuevas tecnologías que beneficien a los pacientes mientras crean valor para los accionistas.
하모니 바이오사이언스 (Nasdaq: HRMY)는 론 필립을 이사회에 임명했습니다. 현재 Orbital Therapeutics의 사장 겸 CEO인 필립은 기업 구축, 조직 성장 및 치료 개발 분야에서 30년의 경험을 가지고 있습니다. 그의 주목할 만한 이전 역할은 Spark Therapeutics의 CEO로, 유전성 실명에 대한 새로운 유전자 치료의 상업적 출시를 이끌고 회사의 치료 플랫폼을 확장했습니다.
필립의 광범위한 배경에는 화이자와 와이어스에서의 리더십 직책이 포함되어 있으며, 아프리카/중동 지역의 사장으로 재직하며 다양한 전략적 이니셔티브를 이끌었습니다. 현재 그는 City Therapeutics와 Life Sciences Cares Pennsylvania의 이사로 활동하고 있습니다. 이번 임명은 하모니가 사업 개발을 통해 파이프라인 확장을 목표로 하는 것과 일치하며, Philip의 전문 지식을 활용하여 환자에게 혜택을 주고 주주 가치를 창출하는 새로운 기술을 식별하는 데 중점을 두고 있습니다.
Harmony Biosciences (Nasdaq: HRMY) a nommé Ron Philip à son Conseil d'Administration. Philip, actuellement Président et CEO d'Orbital Therapeutics, apporte 30 ans d'expérience dans la construction d'entreprises, la croissance organisationnelle et le développement thérapeutique. Son rôle précédent le plus notable a été celui de CEO de Spark Therapeutics, où il a dirigé le lancement commercial d'une nouvelle thérapie génique pour la cécité héréditaire et a élargi la plateforme thérapeutique de l'entreprise.
Le parcours de Philip comprend des postes de direction chez Pfizer et Wyeth, où il a été président régional pour l'Afrique/Moyen-Orient et a dirigé diverses initiatives stratégiques. Il siège actuellement aux conseils d'administration de City Therapeutics et de Life Sciences Cares Pennsylvania. La nomination s'inscrit dans l'optique d'Harmony de développer son portefeuille par le biais de l'expansion commerciale, alors que l'entreprise vise à tirer parti de l'expertise de Philip pour identifier de nouvelles technologies bénéfiques pour les patients tout en créant de la valeur pour les actionnaires.
Harmony Biosciences (Nasdaq: HRMY) hat Ron Philip in seinen Vorstand berufen. Philip, der derzeit Präsident und CEO von Orbital Therapeutics ist, bringt 30 Jahre Erfahrung im Unternehmensaufbau, in der organisatorischen Entwicklung und in der therapeutischen Entwicklung mit. Seine bemerkenswerteste vorherige Rolle war die des CEO von Spark Therapeutics, wo er den kommerziellen Start einer neuartigen Gentherapie für erbliche Blindheit leitete und die therapeutische Plattform des Unternehmens erweiterte.
Philips umfangreicher Hintergrund umfasst Führungspositionen bei Pfizer und Wyeth, wo er als regionaler Präsident für Afrika/Mittlerer Osten tätig war und verschiedene strategische Initiativen leitete. Derzeit sitzt er in den Vorständen von City Therapeutics und Life Sciences Cares Pennsylvania. Die Ernennung steht im Einklang mit dem Fokus von Harmony auf die Erweiterung des Portfolios durch Geschäftsentwicklung, da das Unternehmen plant, Philips Fachwissen zur Identifizierung neuer Technologien zu nutzen, die den Patienten zugutekommen und gleichzeitig den Aktionärswert steigern.
- Addition of experienced biotech executive with proven track record in commercial launches and business development
- Strategic alignment with company's focus on pipeline expansion
- Brings valuable expertise in identifying and acquiring new technologies
- None.
Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business development. Prior to being CEO, he served as Chief Operating Officer and Chief Commercial Officer at Spark.
“I am excited to join the Harmony Biosciences board during the company’s transformative phase of growth,” said Philip. “Harmony’s success building a strong, durable business and a robust pipeline of innovative late-stage assets across multiple therapeutic areas provides a solid foundation to help thousands of patients with limited treatment options while generating durable, long-term value creation. I am eager to share my experiences and support the company’s growth at this very exciting time.”
“Ron shares our focus on expanding the pipeline through business development, which is very relevant as Harmony continues to grow,” said Jeff Aronin, Harmony Biosciences founder and chairman. “He has a proven ability to identify new technologies that help meet patients’ needs while delivering value to our shareholders.”
Before joining Spark, Philip spent a decade at Pfizer and Wyeth, where he held several senior leadership roles, including regional president for
Philip currently serves as a board member at City Therapeutics and at Life Sciences Cares Pennsylvania. He was previously on the boards of the Academy of Natural Sciences of Drexel University, the Chamber of Commerce for
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403522784/en/
Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
Source: Harmony Biosciences Holdings, Inc.
FAQ
What experience does Ron Philip bring to Harmony Biosciences' (HRMY) board?
How will Ron Philip's appointment impact HRMY's business development strategy?
What was Ron Philip's most significant achievement at Spark Therapeutics?
What other board positions does Ron Philip currently hold?
